26 results
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals Inc
2 May 24
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
4:10pm
and professional fees, offset by a decrease of $0.1 million in insurance expenses.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc
8-K
EX-99.2
LBPH
Longboard Pharmaceuticals Inc
12 Mar 24
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
4:10pm
modulator Rapid onset & offset of action Highly selective to S1PR1,5 No impact on S1PR2,3 in preclinical models High oral bioavailability with direct
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals Inc
12 Mar 24
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
4:10pm
research expenses and $0.2 million of other miscellaneous expenses, offset by a decrease of $0.3 million in preclinical and clinical trial expenses … in personnel-related costs, $1.2 million of professional services and consulting expenses, and $0.4 million of other miscellaneous expenses, offset
8-K
EX-99.1
lmi 8kzf9xzcx
29 Nov 23
Regulation FD Disclosure
8:35am
8-K
EX-99.1
n2y 8hm2w1ugo5w
2 Nov 23
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
s5x5d0ns9j2u0
5 May 22
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am
DEF 14A
4z8f e1balwd5ghhw
13 Apr 22
Definitive proxy
4:15pm
10-K
y88mzx49y
3 Mar 22
Annual report
4:31pm
8-K
EX-99.1
1rnh1bg
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
e2mvyj64rd9fsgbythed
1 Dec 21
Regulation FD Disclosure
9:01am
424B4
lfhb58v24goxj5mdb0o6
12 Mar 21
Prospectus supplement with pricing info
5:02pm
S-1/A
ubpc09cgbktyb
8 Mar 21
IPO registration (amended)
6:13am